Ask AI
ProCE Banner Activity

ART-PRO: 48-Week Results of DTG + 3TC for Maintenance of Virologic Suppression in Patients With Historical 3TC Resistance

Slideset Download
Conference Coverage
This proof-of-concept study demonstrated that switching to DTG + 3TC maintained virologic control in INSTI-naive patients with historical 3TC resistance but no 3TC resistance-associated mutations in proviral DNA at baseline according to Sanger sequencing.

Released: November 16, 2019

Expiration: November 14, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare